GlassScriptPhysician profile
Rochelle M Cunningham
NPI 1508815887
$5,931.68
in general payments reported to CMS, 2019-2025
21 companies · $4,048 in 2025
The $4,048 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $209 · 2021: $140 · 2022: $91.58 · 2023: $401 · 2024: $743 · 2025: $4,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,543 · Food and Beverage: $1,587 · Education: $63.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,542.50 |
| Food and Beverage | $1,586.96 |
| Education | $63.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $3,587.50 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $272.09 | 2019-2024 | Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.70 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $213.15 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $181.68 | 2021-2024 | |
| Novo Nordisk INC | $159.32 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Mallinckrodt Hospital Products INC. | $137.63 | 2020-2025 | Terlivaz |
| Horizon Therapeutics Plc | $133.05 | 2023 | Krystexxa |
| Glaxosmithkline, LLC. | $126.64 | 2023 | |
| Amgen INC. | $126.13 | 2024-2025 | Tavneos |
| Calliditas Therapeutics US INC. | $125.04 | 2024 | |
| Akebia Therapeutics INC | $120.88 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $120.00 | 2025 | Lupkynis |
| Vifor Pharma, INC. | $101.55 | 2019 | |
| Pfizer INC. | $94.52 | 2019-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $43.60 | 2023-2025 | Filspari |
| Abbvie INC. | $32.65 | 2019 | |
| Biogen, INC. | $27.86 | 2025 | Skyclarys |
| Lilly USA, LLC | $26.78 | 2024 | Jardiance |
| Ardelyx, INC. | $20.43 | 2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rochelle Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.